Insights
What we publish, we have lived through on a mandate.
Current thinking on healthcare, life sciences, and capital in the GCC. No trend pieces, no reheated news, just the reads we would give a client working the same decision.
UAE healthcare regulatory & deal tracker Every instrument that changed how deals price, with the primary source for each.
Regulatory Brief7 September 2026The UAE's transplant regulations put an open-ended tail on every health insurer in the country, and gave them six months to price itWhat Cabinet Resolution 61/2026 requires of transplant facilities and of UAE health insurers, and why the phrase about complications regardless of when they are discovered is the provision to read twice.Regulatory Brief7 September 2026DHA re-issued its social media advertising standard in August. It has been in force since October 2022, and most Dubai clinic feeds breach itWhat the DHA Standards for Medical Advertisement Content on Social Media actually prohibit, why a 2026 circular about a 2022 standard is an enforcement signal, and how historic content becomes a licence-level diligence item.Regulatory Brief7 September 2026Abu Dhabi's Emiratisation shortfall does not reset in January. It compounds, and the penalty list ends at the Daman-Thiqa networkWhat DoH Circular 164/2026 does to the workforce line in an Abu Dhabi healthcare operating model, and why an acquired facility's Emiratisation gap is priced as a multi-year liability rather than a one-year fine.
- 7 September 2026Deal BriefThiqa pays for social egg freezing in Abu Dhabi. The eligibility gate is narrow enough to change what a fertility clinic is worthHow the Thiqa social egg freezing policy defines its covered cohort, and what the eligibility gate, the psychological assessment and the five-year storage limit do to the valuation of a UAE assisted-reproduction asset.
- 7 September 2026Regulatory BriefBahrain terminated its traceability hub provider, then built its own. If you place devices on that market, registration opened in AprilWhat NHRA's medical devices and supplies traceability programme requires, who is captured in the first phase, and what the phased design means for a distributor or manufacturer treating Bahrain as a secondary GCC market.
- 7 September 2026Regulatory BriefDubai gives you until 30 January 2027 to appoint a licensed child protection specialist. Abu Dhabi's version has been live since JuneWhat the DHA child protection standard requires of Dubai facilities before 30 January 2027, how the Abu Dhabi policy already in force differs, and what a provider group operating across both has to build.
- 4 September 2026Regulatory BriefAbu Dhabi's Thiqa obesity policy and the daily-oral GLP-1: what a UAE weight-management clinic is actually worthWhat the Thiqa TRP-OMM policy and the DoH Foundayo announcement mean for the valuation of a UAE weight-management or aesthetic clinic running on GLP-1 revenue.
- 4 September 2026Deal BriefGCC listed hospital operators H1 2026: the occupancy number that reprices every private clinic dealThe listed-operator interim comps that reset the negotiating floor for GCC private hospital and clinic transactions in H1 2026.
- 23 August 2026Regulatory BriefDubai's DHA clinical research standards: trial revenue has a compliance deadline of 1 January 2027What DHA/HRS/MERD/ST-02 does to Dubai clinical-trial sponsors, CROs, and hospitals — and why a deal closing before 1 January 2027 treats it as a covenant, not a breach.
- 22 August 2026Regulatory BriefThe UAE is approving new medicines before the rest of the world. That changes launch sequencing.What two EDE approvals in sixteen days do to filing sequence, UAE revenue timing, and the economics of distribution agreements signed when the UAE was a late-launch market.
- 21 August 2026Regulatory BriefDoH Abu Dhabi's tele-mental health standard: a new licence gateWhat Standard DoH/ST/SCTMHS/HQS/V1/2026 does to the market-entry and diligence line for any Abu Dhabi mental-health target with remote consultation revenue.
- 21 August 2026M&A ReadAbu Dhabi's mental-health capacity doubling: reading a dated demand statement against a new licence gateWhat the 3 August 2026 DoH capacity statement means for a buyer of an Abu Dhabi mental-health platform, read against the licence, Malaffi and AAMEN barriers a target must already clear.
- 20 August 2026Regulatory BriefDoH Abu Dhabi's DME policy V2: home medical equipment, repricedWhat Policy/DME/HPS/V2/2026 does to DME distributors, home-health providers, and DoH-authorised payers in Abu Dhabi — and where the diligence lines move.
- 15 August 2026Regulatory BriefUAE's Ministerial Decision 91 of 2026: transplant capacity is now a fundable expansionHow UAE Ministerial Decision No. 91 of 2026 and the Hayat programme numbers published alongside it reprice transplant capacity for hospital operators, transplant programmes, insurers and investors.
- 12 August 2026Regulatory BriefCDSCO closes the Phase III global-trial shortcut: India-first approvals no longer skip the IND DivisionWhat CDSCO's 10 August 2026 circular on Phase III Global Clinical Trials with Indian subjects means for MNC sponsors, India-based biotech, and the biotech funds valuing India-first approvals.
- 11 August 2026Regulatory BriefDubai Resolution 49: free zones are inside DHA nowWhy operators who built in a Dubai free zone to sit outside DHA are now inside its perimeter, and what Resolution 49/2024 does to a licence in a sale.
- 11 August 2026Regulatory BriefIRDAI's 2026 TPA amendment: what it repricesWhat the 30 July 2026 IRDAI TPA amendment does to the value and the control structure of an Indian third-party administrator.
- 31 July 2026Regulatory BriefUAE EDE's 3PL model: enter pharma distribution without your own warehouseWhat the EDE's 29 July 2026 3PL storage model does to the capex line, the deal thesis, and the entry sequence for anyone chasing a UAE pharmaceutical distribution licence.
- 9 July 2026Regulatory BriefClinical AI in Abu Dhabi now needs a governance fileUnder the DoH Responsible AI Standard, every clinical AI tool a group deploys needs documented explainability, privacy controls, and accountability sign-off.
- 8 July 2026Market AccessUAE family office: DIFC vs ADGM, decided firstHow high-net-worth families should structure a UAE family office and holding vehicles across DIFC and ADGM, and why the framework has to be settled before assets are transferred.
- 8 July 2026Deal BriefDiligence on a hospital group: what moves priceDiligence on a multi-site medical-center network or hospital group is a discipline in itself, and the findings that reprice a deal sit in payer concentration, denial rates, per-facility licence conditions, health-information connectivity, and the new UAE merger-control regime.
- 8 July 2026Regulatory BriefClinical costing: can your ERP reconcile to the EMR?Abu Dhabi's patient-level clinical costing requirement exposes the ERP-to-EMR integration gap most mid-size hospital groups still carry.
- 6 July 2026Strategy BriefAbu Dhabi's advanced-therapy land grabAbu Dhabi's wave of BIO 2026 advanced-therapy partnerships opens a positioning window for provider groups with research infrastructure to become trial sites and centres of excellence.
- 5 July 2026Infrastructure BriefAbu Dhabi's AED 55bn PPP pipeline: position nowAbu Dhabi's AED 55 billion PPP pipeline opens a health-infrastructure opportunity that rewards sponsors who arrive with grounded feasibility and a bankable financial model.
- 4 July 2026Board BriefWhy geopolitical risk is now a GCC board agenda itemHow Red Sea logistics, war-risk exclusions, and force majeure disputes moved geo-risk onto the GCC board agenda.
- 4 July 2026Strategy BriefEntering UAE healthcare: the sequence that worksWhy UAE healthcare entries fail on sequence rather than strategy, and the order that actually works.
- 4 July 2026Deal BriefUAE healthcare M&A: what 2026 buyers pay forThe gap between what sellers think drives a healthcare valuation and what 2026 buyers actually pay a premium for.
- 1 July 2026Market AccessGCC expansion: one market is not sixWhy GCC expansion demands country-by-country entry across six markets, disciplined distributor due diligence, and a Saudi strategy that does not assume the UAE approach carries over.
- 1 July 2026Deal BriefFinancing a buy-and-build healthcare platformThe right mix of debt and equity for a scaling hospital or medical-center-group platform depends on its cash generation and its stage, and the GCC's 2026 capital markets now offer sukuk, private equity, and staged structures to match each one.
- 25 June 2026Workforce BriefThe 2027 Emiratisation clock on clinical rolesThe UAE's 2027 rule directing half of the 2% Emiratisation target to clinical roles turns Emiratisation into a workforce-planning problem your group should be solving through 2026.
- 23 June 2026Deal BriefWhat earns a 10x healthcare multipleAmanat's completion of full ownership of Cambridge Health Group at an implied ~10.5x EBITDA on our own arithmetic shows that scale and margin quality, not top-line revenue, are what command the platform multiple.
- 19 June 2026Market AccessUAE pharma manufacturing: a nine-stage buildThe nine-stage path from feasibility to WHO or EU GMP certification for UAE pharmaceutical manufacturing, and why localisation incentives do not shorten the qualification clock.
- 16 June 2026Strategy BriefThe runway before a DFM or ADX listingWhy the premium multiple on a DFM or ADX listing is earned in the 18-to-24-month readiness window, and what an 18-point readiness assessment tests before the transaction begins.
- 13 June 2026Risk BriefForce majeure will not save an unwritten clauseWhy force majeure protection depends on clause scope and notification discipline, and how sanctions exposure can crystallise on contracts signed long before a designation.
- 12 June 2026Regulatory BriefDubai built a new licence line for longevity clinicsDubai's Law No. 17 of 2026 has been in force since 13 June. Article 7(a) prohibits the longevity Activity without an Authority permit across the Emirate, free zones and the DIFC included, with no grandfathering, while the permit conditions themselves have not issued.
- 11 June 2026Operations BriefA high denial rate costs you moreDenial rates of 12-22% against a managed benchmark below 5% are a bigger prize than pricing, and Avior runs revenue cycle as a discipline rather than a reaction.
- 9 June 2026Regulatory BriefEDE drug registration: there is no verification routeHow UAE marketing authorisation actually works under the Emirates Drug Establishment: one standard eCTD route scaled by product class, a separate 90-working-day pricing clock, and no reliance pathway for products approved by the FDA or EMA.
- 5 June 2026Operations BriefWhere the missing margin points wentThe gap between a 4% margin and a 12-18% benchmark is built and lost in service-line economics, pricing and procurement, and Avior recovers it with tracked impact.
- 28 May 2026Market AccessDHA and DoH licensing: sequence before leaseWhy UAE healthcare facility licensing under DHA or DoH must run in strict sequence, and how a stage-two decision determines what happens at stage six.
- 22 May 2026Regulatory BriefThree emirates, three compliance regimes, one calendarA multi-site group across Dubai, Abu Dhabi and Sharjah now carries three renewal calendars, three connectivity mandates and three penalty schedules, and needs one unified compliance spine to govern them.
- 21 May 2026Regulatory BriefSharjah tightened its health rulebook: map your sitesSharjah's 2026 amendment adds administrative penalties across government, private and free-zone facilities and their professionals, so groups with Sharjah sites need a Sharjah-specific policy map and a per-clinician re-credentialing plan.
- 16 May 2026Deal BriefWhy healthcare and pharma M&A is differentWhat separates a healthcare or pharma acquisition from generic M&A, and why the valuation runs longer.
- 12 May 2026Market AccessUAE business setup: free zone, mainland or DIFCWhy the free zone, mainland and DIFC or ADGM decision must be modelled against Corporate Tax and banking at establishment, not treated as paperwork.
- 9 May 2026Deal BriefArada's Reem deal opens a new exit routeA property developer's AED 2 billion commitment to Reem Hospital signals that strategics chasing recurring revenue now sit alongside PE and sovereigns as credible buyers for scalable multi-site healthcare brands.
- 22 April 2026Regulatory BriefUAE merger control hits healthcare dealsThe UAE's new merger-control regime forces pre-closing clearance on many healthcare deals, so regulatory runway and UBO disclosure now belong in the deal timeline.
- 26 February 2026Regulatory BriefThe end of UAE pharma exclusivityThe end of the exclusive-distributor model in the UAE is an M&A and re-contracting catalyst that favours distributors with cold-chain, hospital and tender infrastructure.
- 18 November 2025Regulatory BriefDubai's claims rulebook now puts your permit at riskDubai's PD-05-2025 rebuilds the claim lifecycle around eClaimLink with hard SLAs and permit-level penalties, forcing hospital and medical-center groups to run revenue cycle natively rather than around the system.
- 3 November 2025Regulatory BriefDay-case DRG in Abu Dhabi: coding now sets marginAbu Dhabi's move to case-based DRG for day-case procedures shifts margin from fee-for-service billing to coding accuracy and resource control.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.